101
|
Beau-Faller M, Cadranel J. Reply to the letter to the editor ‘Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients’ by Krawczyk et al. Ann Oncol 2016; 27:359-60. [DOI: 10.1093/annonc/mdv564] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
102
|
auzou L, Auzou L, Rozensztajn N, Issoufaly T, Vieira T, Assouad J, Baud M, Epaud C, Rosencher L, Antoine M, Coté J, Wislez M, Cadranel J, Lavolé A. L’aspect organisationnel intra-hospitalier est un facteur indépendant d’allongement du délai de prise en charge du cancer bronchopulmonaire (CBP). Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
103
|
Crequit P, Ruppert A, Rozensztajn N, Gounant V, Vieira T, Poulot V, Antoine M, Chouaid C, Wislez M, Cadranel J, Lavolé A. Statut mutationnel EGFR et KRAS dans une cohorte de personnes vivant avec le VIH et présentant un cancer broncho-pulmonaire. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
104
|
Soyez B, Borie R, Cadranel J, Chavez L, Cottin V, Gomez E, Lainé C, Marchand-Adam S, Marquette C, Naccache J, Nunes H, Reynaud-Gaubert M, Savale L, Tazi A, Wemeau L, Crestani B. Effets du rituximab dans la liprotéinose alvéolaire auto-immune. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
105
|
Crequit P, Trinquart L, Yavchitz A, Cadranel J, Ravaud P. Manque d’exhaustivité dans les revues systématiques des traitements de 2e ligne des cancers bronchiques non à petites cellules métastatiques. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
106
|
Cadranel J, Quoix E, Duruisseaux M, Friard S, Fabre E, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Dansin E, Scherpereel A, Hiret S, Coudert B, Souquet P, Wislez M, Morin F, Zalcman G, Barlesi F, Missy P. Valeur pronostique du statut moléculaire de KRAS, EGFR et ALK dans la cohorte prospective IFCT-PREDICT.amm de carcinomes bronchiques non à petites cellules (CBNPC) étendus, non préalablement traités. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
107
|
Sese L, Nunes H, Cottin V, Carton Z, Israel-Biet D, Crestani B, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Guillot-Dudoret S, Nardi A, Dury S, Giraud V, Juvin K, Borie R, Valeyre D, Annesi-Maseano I. Rôle de la pollution atmosphérique dans l’histoire naturelle de la fibrose pulmonaire idiopathique. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
108
|
Pluvy J, Fleury-Feith J, Izadifar A, Febvre M, Naccache J, Cadranel J, Gounant V. Apport de l’examen cytologique extemporané (ROSE « Rapid On-Site Examination ») dans les ponctions transbronchiques à l’aiguille échoguidées (EBUS-PTBA). Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
109
|
Domblides C, Antoine M, Vieira T, Crequit P, Rodenas A, Hamard C, Cadranel J, Lavolé A, Wislez M. Expression de PD-L1 et réponse immunitaire chez les personnes vivant avec le VIH atteintes d’un cancer bronchique. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
110
|
Le Vavasseur B, Gerin M, Similowsky T, Cadranel J, Tourret J, Ronco P, Rondeau E, Benveniste O, Caumes E, Canestri A, Bourgarit A, Carcelain G. Intérêt des IGRAs (Quantiferon TBG-IT®, Tspot-TB®) dans les liquides biologiques pour le diagnostic de tuberculose extrapulmonaire. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
111
|
Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Swallow E, Galebach P, Stein K, Marinsek N, Zhang J. 3087 Characteristics and treatment patterns of ALK+ NSCLC patients who receive second-generation ALK inhibitors: A chart review study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31728-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
112
|
Arrieta O, Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Macalalad A, Kercheval J, Stein K, Weiss J, Zhang J. 3114 Testing and treatment practice of oncologists managing ALK+ NSCLC: international physician survey across four regions. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31755-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
113
|
Cadranel J, Quoix E, Duruisseaux M, Friard S, Fabre E, Daniel C, Westeel V, Madroszyk A, Lena H, Merle P, Mazieres J, Dansin E, Scherpereel A, Hiret S, Coudert B, Souquet P, Missy P, Morin F, Zalcman G, Barlesi F. 3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31769-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
114
|
Park K, Cadranel J, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Guerin A, Kageleiry A, Stein K, Marinsek N, Zhang J. 3108 Treatment Patterns and Survival among ALK+ Non-Small Cell Lung Cancer (NSCLC) Patients: A Chart Review Study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31749-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
115
|
Loubiere S, Wislez M, Beau-faller M, Nanni-metellus I, Garcia S, Chenard M, Ghnassia J, Lacave R, Antoine M, Sobol H, Paciencia-gros M, Escande F, Copin M, Morin F, Missy P, Cadranel J, Barlesi F, Auquier P. 1239 Microcosting evaluation of prognostic/predictive biomarkers performed in a large French prospective cohort of non previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30543-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
116
|
Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T, Rouquette I, Thivolet-Bejui F, Ung M, Poulot V, Schlick L, Moro-Sibilot D, Antoine M, Cadranel J, Lemoine A, Wislez M. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. Ann Oncol 2015; 26:1748-53. [DOI: 10.1093/annonc/mdv232] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2015] [Accepted: 05/07/2015] [Indexed: 02/06/2023] Open
|
117
|
|
118
|
Giroux Leprieur E, Antoine M, Vieira T, Rozensztajn N, Ruppert AM, Rabbe N, Cadranel J, Wislez M. [Role of the Sonic Hedgehog pathway in thoracic cancers]. Rev Mal Respir 2015; 32:800-8. [PMID: 25794996 DOI: 10.1016/j.rmr.2014.11.069] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Accepted: 11/17/2014] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Sonic Hedgehog (Shh) pathway is physiologically activated during embryogenesis and development. It plays a role in idiopathic lung fibrosis and is also activated in several solid cancers. STATE OF THE ART Shh pathway is reactivated in thoracic cancers, as small cell lung carcinoma, non-small cell lung carcinoma and malignant pleural mesothelioma. Shh pathway is associated with cancer stem cells and seems to have a crucial role in tumor proliferation, aggressiveness and chemoresistance in these cancers. This review describes the activation mode of Shh pathway in thoracic cancers and its role in small cell lung carcinoma, non-small cell lung carcinoma and malignant pleural mesothelioma, using in vitro and in vivo models. Notably, data from literature show that inhibition of Shh pathway has an antitumor action and sensitizes to chemotherapy. PERSPECTIVES These results incite to develop targeted therapies against Shh pathway in the treatment of thoracic cancers.
Collapse
Affiliation(s)
- E Giroux Leprieur
- Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; EA4340 BCOH, service de pneumologie et oncologie thoracique, hôpital Ambroise-Paré, AP-HP, université Versailles-Saint-Quentin-en-Yvelines, 92100 Boulogne-Billancourt, France
| | - M Antoine
- Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France
| | - T Vieira
- Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie et de réanimation, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris, France
| | - N Rozensztajn
- Service de pneumologie et de réanimation, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris, France
| | - A-M Ruppert
- Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie et de réanimation, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris, France
| | - N Rabbe
- Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France
| | - J Cadranel
- Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie et de réanimation, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris, France
| | - M Wislez
- Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie et de réanimation, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris, France.
| |
Collapse
|
119
|
Leprieur EG, Vieira T, Antoine M, Rozensztajn N, Rabbe N, Schlick L, Cadranel J, Wislez M. L’activation de la voie Sonic Hedgehog est associée à la résistance à la chimiothérapie à base de sels de platine dans le cancer bronchique non à petites cellules. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
120
|
Vieira T, Antoine M, Duruisseaux M, Rabbe N, Schlick L, Poulot V, Rodenas A, Cadranel J, Wislez M. Facteurs associés à l’expression de PD-L1 dans les carcinomes sarcomatoïdes. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
121
|
Herve V, Rabbe N, Guilleminault L, Paul F, Schlick L, Azzopardi N, Duruisseaux M, Fouquenet D, Montharu J, Redini F, Paintaud G, Lemarié E, Cadranel J, Wislez M, Heuzé-Vourc’h N. Aérosolthérapie anti-VEGF dans les adénocarcinomes pulmonaires primitifs mutés pour K-ras. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
122
|
Blumenschein GR, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Ann Oncol 2015; 26:894-901. [PMID: 25722381 DOI: 10.1093/annonc/mdv072] [Citation(s) in RCA: 255] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Accepted: 02/11/2015] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. PATIENTS AND METHODS Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. RESULTS One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. CONCLUSION Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. CLINICALTRIALSGOV REGISTRATION NUMBER NCT01362296.
Collapse
Affiliation(s)
- G R Blumenschein
- MD Anderson Cancer Center, The University of Texas, Houston, USA.
| | - E F Smit
- Department of Pulmonary Diseases, Vrije Universiteit VU Medical Centre, Amsterdam, The Netherlands
| | - D Planchard
- Medical Oncology Department, Gustave Roussy (GR), Villejuif, France
| | - D-W Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - J Cadranel
- Department of Respiratory Medicine, Hôpital Tenon, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - T De Pas
- European Institute of Oncology, Milan, Italy
| | - F Dunphy
- Duke University Medical Center, Durham, USA
| | - K Udud
- Korányi National Institute of Tuberculosis and Pulmonology, Budapest, Hungary
| | - M-J Ahn
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - N H Hanna
- IU Melvin and Bren Simon Cancer Center, Indianapolis, USA
| | - J-H Kim
- Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - J Mazieres
- Hopital Larrey CHU Toulouse, Toulouse, France
| | - S-W Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - P Baas
- Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | | - S Redhu
- GlaxoSmithKline, Collegeville, USA
| | - A Puski
- GlaxoSmithKline Kft., Budapest, Hungary
| | - F S Wu
- GlaxoSmithKline, Collegeville, USA
| | - P A Jänne
- Lowe Center for Thoracic Oncology, Belfer Institute for Applied Cancer Science Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
123
|
Créquit P, Tran Q, Morin F, Zalcman G, Westeel V, Cadranel J. Qu’est-ce qu’une thérapeutique innovante (TI) en cancérologie en 2014 : sondage auprès de l’intergroupe francophone de cancérologie thoracique (IFCT). Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
124
|
Vieira T, Antoine M, Rabbe N, Schlick L, Poulot V, Rodenas A, Lavole A, Cadranel J, Wislez M. Facteurs associés à l’expression de PD-L1 dans les carcinomes sarcomatoïdes. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.11.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
125
|
Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavolé A, Gounant V, Fillon J, Antoine M, Cadranel J. Pneumopathie interstitielle diffuse à la prise de Crizotinib. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
126
|
Cottin V, Bergot E, Bourdin A, Cadranel J, Camus P, Crestani B, Dalphin JC, Dromer C, Israel-Biet D, Jouneau S, Kessler R, Marchand-Adam G, Marquette C, Prévot G, Reynaud-Gaubert M, Valeyre D, Wallaert B, Bouquillon B, Cordier JF. Seconde enquête de pratique sur la prise en charge de la fibrose pulmonaire idiopathique en France. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
127
|
Tabeze L, Borie R, Cottin V, Nathan N, Nunes H, Naccache J, Valeyre D, Cadranel J, Amselem S, Tazi A, Israel-Biet D, Marchand-Adam S, Prevot G, Reynaud Gaubert M, Clement A, Cordier J, Crestani B, Kannengiesser C. Prévalence de mutations identifiées dans les suspicions de formes génétiques de fibroses. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.11.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
128
|
Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Bièche I, Lizard S, De Fraipont F, Morin F, Zalcman G, Pignon J, Cadranel J. Ermetic-2 Project : Impact of Systematic Egfr and Kras Mutation Evaluation By Alternative Testing Methods on Progression-Free (Pfs) and Overall Survival (Os) in Patients with Advanced Non–Small-Cell Lung Cancer (Nsclc) Treated By Erlotinib (E) in the Ifct Ermetic Cohort. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
129
|
Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A. The PI3K/AKT pathway promotes gefitinib resistance in wild-type EGFR lung adenocarcinoma by a deacetylase-dependent mechanism. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
130
|
Vieira T, Antoine M, Poulot V, Schlick L, Rabbe N, Rodenas A, Duruisseaux M, Fallet V, Lacave R, Cadranel J, Wislez M. Profil anatomo-clinique et moléculaire des carcinomes bronchopulmonaires primitifs de type sarcomatoïde. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
131
|
Ferrand H, Crockett F, Naccache JM, Rioux C, Mayaud C, Yazdanpanah Y, Cadranel J. [Pulmonary manifestations in HIV-infected patients: a diagnostic approach]. Rev Mal Respir 2014; 31:903-15. [PMID: 25496788 DOI: 10.1016/j.rmr.2014.04.106] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2013] [Accepted: 04/25/2014] [Indexed: 01/12/2023]
Abstract
The spectrum of pulmonary diseases that can affect human immunodeficiency virus (HIV)-infected patients is wide and includes both HIV and non-HIV-related conditions. Opportunistic infections and neoplasms remain a major concern even in the current era of combination antiretroviral therapy. Although these diseases have characteristic clinical and radiological features, there can be considerable variation in these depending on the patient's CD4 lymphocyte count. The patient's history, physical examination, CD4 count and chest radiograph features must be considered in establishing an appropriate diagnostic algorithm. In this article, we propose different diagnostic approaches HIV infected to patients with respiratory symptoms depending on their clinico-radiological pattern.
Collapse
Affiliation(s)
- H Ferrand
- Service de pneumologie, hôpital Tenon, université P&M Curie, AP-HP, 4, rue de la Chine, 75970 Paris, France; Service de maladies infectieuses et tropicales, hôpital Bichat-Claude-Bernard, université Denis-Diderot, AP-HP, Paris, France
| | - F Crockett
- Service de pneumologie, hôpital Tenon, université P&M Curie, AP-HP, 4, rue de la Chine, 75970 Paris, France
| | - J-M Naccache
- Service de pneumologie, hôpital Tenon, université P&M Curie, AP-HP, 4, rue de la Chine, 75970 Paris, France
| | - C Rioux
- Service de maladies infectieuses et tropicales, hôpital Bichat-Claude-Bernard, université Denis-Diderot, AP-HP, Paris, France
| | - C Mayaud
- Service de pneumologie, hôpital Tenon, université P&M Curie, AP-HP, 4, rue de la Chine, 75970 Paris, France
| | - Y Yazdanpanah
- Service de maladies infectieuses et tropicales, hôpital Bichat-Claude-Bernard, université Denis-Diderot, AP-HP, Paris, France
| | - J Cadranel
- Service de pneumologie, hôpital Tenon, université P&M Curie, AP-HP, 4, rue de la Chine, 75970 Paris, France.
| |
Collapse
|
132
|
Gounant V, Khalil A, Créquit P, Lavole A, Ruppert AM, Antoine M, Milleron B, Wislez M, Carette MF, Assouad J, Cadranel J. 2014 update on non-small cell lung cancer (excluding diagnosis). Diagn Interv Imaging 2014; 95:721-5. [PMID: 25027710 DOI: 10.1016/j.diii.2014.05.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Lung cancer (LC) is a major public health issue because of its frequency, but especially because of the severity of this disease. The epidemiology has changed with an increased incidence in non-smokers and women. The ATS/ERS/IASLC classification of adenocarcinomas was modified in 2011, and they are now the most frequent histological subtype. More than half the cases of LC are diagnosed at the metastatic stage. Biopsies must provide tissue samples that are quantitatively large enough and of a good enough quality for diagnosis and to search for biomarkers. When the cancer seems to be localized, precise staging must be obtained. Treatment is based on the TNM classification. In localized stages, lobectomy associated with lymph node dissection is the standard therapy. Intraoperative chemotherapy improves survival in case of lymph node infiltration. Stereotactic radiation therapy and radiofrequency can be considered as specific cases. In cases with local progression, treatment is more controversial. In the presence of metastases, the goal is not a cure, but improving survival and quality of life. Numerous advances have been made with personalized treatment, (in particular in relation to the histological type and oncogenic addiction in tumors, access to new drugs, and improved management). Clinical research in thoracic cancer is very active. The fight against tobacco should remain a priority.
Collapse
Affiliation(s)
- V Gounant
- Sorbonne Universités, UPMC Université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie, Centre expert en oncologie thoracique et maladies pulmonaires rares, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Service de chirurgie thoracique, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
| | - A Khalil
- Service de radiologie, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - P Créquit
- Sorbonne Universités, UPMC Université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie, Centre expert en oncologie thoracique et maladies pulmonaires rares, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - A Lavole
- Sorbonne Universités, UPMC Université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie, Centre expert en oncologie thoracique et maladies pulmonaires rares, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - A M Ruppert
- Sorbonne Universités, UPMC Université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie, Centre expert en oncologie thoracique et maladies pulmonaires rares, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - M Antoine
- Sorbonne Universités, UPMC Université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service d'anatomie pathologique, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - B Milleron
- Service de pneumologie, Centre expert en oncologie thoracique et maladies pulmonaires rares, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - M Wislez
- Sorbonne Universités, UPMC Université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie, Centre expert en oncologie thoracique et maladies pulmonaires rares, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - M F Carette
- Service de radiologie, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - J Assouad
- Service de chirurgie thoracique, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - J Cadranel
- Sorbonne Universités, UPMC Université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France; Service de pneumologie, Centre expert en oncologie thoracique et maladies pulmonaires rares, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| |
Collapse
|
133
|
Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll J, Hurbin A. 495: AKT and gefitinib resistance in mutant KRAS non-small cell lung cancers through mechanisms dependent of acetylation. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50440-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
134
|
Comarmond C, Crestani B, Tazi A, Hervier B, Adam Marchand S, Nunes H, Cohen-Aubart F, Wislez M, Cadranel J, Housset B, Lloret-Linares C, Sève P, Pagnoux C, Abad S, Camuset J, Bienvenu B, Duruisseaux M, Hachulla E, Arlet JB, Hamidou M, Mahr A, Resche-Rigon M, Brun AL, Grenier P, Cacoub P, Saadoun D. FRI0460 Pulmonary Fibrosis in Anca-Associated Vasculitis: Clinical Characteristics and Long-Term Followup of 49 Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
135
|
Cadranel J. Aspergilloses pulmonaires chroniques. J Mycol Med 2014. [DOI: 10.1016/j.mycmed.2014.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
136
|
|
137
|
Cottin V, Crestani B, Valeyre D, Wallaert B, Cadranel J, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, Cordier JF, Aguilaniu B, Bouquillon B, Carré P, Danel C, Faivre JB, Ferretti G, Just N, Kouzan S, Lebargy F, Marchand Adam S, Philippe B, Prévot G, Stach B, Thivolet-Béjui F. Erratum à « Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique » [Rev. Mal. Respir. 30 (10) 879–902]. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
138
|
Barlesi F, Blons H, Beau-Faller M, Rouquette I, Ouafik L, Mosser J, Merlio J, Bringuier P, Jonveaux P, Le Marechal C, Denis M, Penault-Llorca F, Debieuvre D, Soria J, Cadranel J, Mazieres J, Missy P, Morin F, Nowak F, Zalcman G. Biomarqueurs France : résultats de l’analyse en routine de EGFR, HER2, KRAS, BRAF, PI3K, et ALK sur 10 000 patients (pts) atteints de cancer bronchique non à petites cellules (CBNPC). Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.041] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
139
|
Lavolé A, Lejeune C, Epaud C, Rosencher L, Ruppert AM, Gounant V, Créquit P, Rousseau-Bussac G, Wislez M, Cadranel J. Délai de prise en charge du cancer du poumon (CP) en hôpital de jour d’un centre expert en oncologie thoracique. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
140
|
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2013; 25:126-31. [PMID: 24285021 DOI: 10.1093/annonc/mdt418] [Citation(s) in RCA: 231] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. PATIENTS AND METHODS EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network. RESULTS Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], worse in smokers than in non-smoker patients with exon 20 mutations (12 versus 21 months; hazard ratio [HR] for death 0.27, 95% CI 0.08-0.87, P = 0.03). Under EGFR-tyrosine kinase inhibitors (TKIs), median OS was 14 months (95% CI 6-21); disease control rate was better for complex mutations (6 of 7, 86%) than for single mutations (16 of 40, 40%) (P = 0.03). CONCLUSIONS Rare EGFR-mutated NSCLCs are heterogeneous, with resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to EGFR-TKIs, probably requiring individual assessment.
Collapse
Affiliation(s)
- M Beau-Faller
- Department of Biochemistry and Molecular Biology, Strasbourg University Hospital, Strasbourg
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
141
|
Lavolé A, Toper C, Belmont L, Ruppert AM, Wislez M, Cadranel J. [Lung cancer and HIV infection]. Rev Mal Respir 2013; 31:133-41. [PMID: 24602680 DOI: 10.1016/j.rmr.2013.07.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 07/11/2013] [Indexed: 01/18/2023]
Abstract
AIDS was the cause of the majority of deaths from HIV infection before 1996 but since the introduction of antiretroviral therapies the causes of mortality have changed considerably. In 2010, 75 % of deaths were due to diseases other than AIDS, the majority being cancers. Lung cancer is the most common in terms of both incidence and mortality. It shows specific features when compared to the general population: there is an excess risk due to heavy smoking but also probably due to immunosuppression. The age of onset is younger and the prognosis worse than in the general population. Management is difficult, partly due to the aggressive nature of the tumor and partly to co-morbidities and potential interactions between anticancer and antiretroviral therapies. A phase II therapeutic trial (IFCT-CHIVA 1001) is under way nationally.
Collapse
Affiliation(s)
- A Lavolé
- Service de pneumologie et réanimation, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France; Équipe de recherche 2 et GRC-UPMC 04 Théranoscan, université Pierre-et-Marie-Curie, université Paris-VI, 75006 Paris, France.
| | - C Toper
- Service de pneumologie et réanimation, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France
| | - L Belmont
- Service de pneumologie et réanimation, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France; Équipe de recherche 2 et GRC-UPMC 04 Théranoscan, université Pierre-et-Marie-Curie, université Paris-VI, 75006 Paris, France
| | - A-M Ruppert
- Service de pneumologie et réanimation, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France; Équipe de recherche 2 et GRC-UPMC 04 Théranoscan, université Pierre-et-Marie-Curie, université Paris-VI, 75006 Paris, France
| | - M Wislez
- Service de pneumologie et réanimation, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France; Équipe de recherche 2 et GRC-UPMC 04 Théranoscan, université Pierre-et-Marie-Curie, université Paris-VI, 75006 Paris, France
| | - J Cadranel
- Service de pneumologie et réanimation, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France; Équipe de recherche 2 et GRC-UPMC 04 Théranoscan, université Pierre-et-Marie-Curie, université Paris-VI, 75006 Paris, France
| |
Collapse
|
142
|
Ruppert AM, Amrioui F, Gounant V, Wislez M, Bouvier F, Cadranel J. Le sevrage tabagique en oncologie thoracique. Rev Mal Respir 2013; 30:696-705. [DOI: 10.1016/j.rmr.2013.02.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2012] [Accepted: 02/23/2013] [Indexed: 11/29/2022]
|
143
|
Giroux Leprieur E, Antoine M, Vieira T, Duruisseaux M, Poulot V, Rabbe N, Belmont L, Gounant V, Lavolé A, Milleron B, Lacave R, Cadranel J, Wislez M. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Lung Cancer 2013; 79:167-72. [DOI: 10.1016/j.lungcan.2012.10.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2012] [Revised: 09/18/2012] [Accepted: 10/16/2012] [Indexed: 11/16/2022]
|
144
|
Gounant V, Ruppert AM, Fenane H, Giol M, Karsenti A, Cadranel J, Assouad J. Épidémiologie des pneumothorax : expérience d’un centre spécialisé « SOS pneumothorax ». Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
145
|
Duruisseaux M, Antoine M, Rodenas A, Rabbe N, Schlick L, Vieira T, Belmont L, Cadranel J, Wislez M. Profil des adénocarcinomes (ADC) lépidiques non-mucineux (NM) et des variants mucineux (M) selon l’expression de MUC1, MUC2, MUC5AC et MUC6. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
146
|
Taillé C, Grootenboer-Mignot S, Nunes H, Carton Z, Cottin V, Israël-Biet D, Cadranel J, Wallaert B, Valeyre D, Chollet-Martin S, Crestani B. Prévalence et pronostic des anticorps antipériplakine au cours de la fibrose pulmonaire idiopathique. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
147
|
Ruppert AM, Gounant V, Gasparini P, Fenane H, Bouvier P, Cadranel J, Assouad J. Pneumothorax spontané primitif : prévalence de la consommation de tabac et de cannabis et échec du sevrage. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
148
|
Borie R, Crestani B, Dieudé P, Nunes H, Allanore Y, Kannengiesser C, Airo P, Matucci-Cerinic M, Wallaert B, Israel-Biet D, Cadranel J, Cottin V, Valeyre D, Grandchamp B. Le polymorphisme commun de MUC5B est associé à la fibrose pulmonaire idiopathique mais pas à l’atteinte interstitielle de la sclérodermie. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
149
|
Duchemann B, Annesi-Maesano I, Jacobe De Naurois C, Liote H, Neuville M, Naccache JM, Boris R, Mekinian A, Mathieu M, Crestani B, Cadranel J, Fain O, Valeyre D, Nunes H. Prévalence et incidence des pneumopathies interstitielles diffuses chroniques (PIDC) en Seine-Saint-Denis (SSD) : analyse à 8 mois. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
150
|
Vieira T, Girard N, Ung M, Monnet I, Bonnette P, Cazes A, Duruisseaux M, Lavole A, Antoine M, Mazieres J, Cadranel J, Wilsez M. Efficacité d’une première ligne de chimiothérapie (CT) chez 97 patients atteints de carcinomes sarcomatoïdes pulmonaires (CS). Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|